• TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis

    المصدر: Nasdaq GlobeNewswire / 18 أبريل 2024 07:00:00   America/New_York

    N/A
شارك على،